🟢 Vera Therapeutics is trading 4.46% up today after TRUTAKNA met all Phase 3 endpoints

Vera Therapeutics is trading at $35.57 (+4.46%) after TRUTAKNA met all prespecified endpoints in the final ORIGIN 3 Phase 3 analysis for IgA nephropathy.

• The 428-patient study showed stabilized kidney function and a 76% reduction in composite kidney-disease progression risk through 104 weeks.
• eGFR results strongly favored treatment over placebo, supporting the company’s planned supplemental FDA filing in the fourth quarter of 2026.